(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 May 2022 (05.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/090203 A1

(51) International Patent Classification:
A61K 38/20 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2021/079636

(22) International Filing Date:
26 October 2021 (26.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20203908.7 26 October 2020 (26.10.2020) EP

(71) Applicant: **CYTUNE PHARMA** [FR/FR]; 3, Chemin du Pressoir Chênaie, 44100 Nantes (FR).

(72) Inventors: **FERRARA, Stefano**; Grabenring 12D, 4123 Allschwil (CH). **MOEBIUS, Ulrich**; Am Rain 7, 82131 Gauting-Unterbrunn (DE). **BÉCHARD, David**; Le Courtil Lie-Dit L'Ornière, 44360 Saint-Etienne de Montluc (FR). **ADKINS, Irena**; Vinorska 370, 25073 Prezletice (CZ). **PODZIMKOVA, Nada**; Kosmonautu 6, 37701 Jindichuv Hradec (CZ).

(74) Agent: **MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH**; Dr. Dirk Bühler, Elisenhof, Elisenstrasse 3, 80335 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2022/090203 A1

(54) **Title:** IL-2/IL-15Rβγ AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA

(57) **Abstract:** The present invention relates to an interleukin-2/interleukin-15 receptor βγ (IL-2/IL- 15Rβγ) agonist for use in the treatment of squamous cell carcinoma. Further provided are dosing schemes for treating patients with squamous cell carcinoma with an IL-2/IL- 15Rβγ agonist.